Alcon
Native name | Alcon AG |
|---|---|
| Company type | Public |
| Industry | Ophthalmology |
| Founded | 1945 in Fort Worth, Texas, United States |
| Headquarters | , Switzerland |
Key people | David Endicott (CEO) |
| Products | |
| Revenue | US$9.91 billion (2024) |
| US$1.41 billion (2024) | |
| US$1.02 billion (2024) | |
| Total assets | US$30.3 billion (2024) |
| Total equity | US$21.6 billion (2024) |
Number of employees | 25,599 (FTE, 2024) |
| Website | alcon |
| Footnotes / references | |
Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.